Brief: Aquestive Therapeutics Receives Conditional FDA Acceptance Of Proprietary Name Anaphylm™ For Lead Candidate Aqst-109 (Epinephrine Sublingual Film)
20/04/2023 13:04
April 20 (Reuters) - Aquestive Therapeutics Inc
AQST.O :
* AQUESTIVE THERAPEUTICS RECEIVES CONDITIONAL FDA ACCEPTANCE
OF
PROPRIETARY NAME ANAPHYLM™ FOR LEAD CANDIDATE AQST-109
(EPINEPHRINE SUBLINGUAL FILM)
Source text for Eikon: ID:nGNX6lsY6w
Further company coverage: AQST.O
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Announces FDA Acceptance Of Anaphylm™ NDA Resubmission And PDUFA Goal Date Of March 16, 2027
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Aquestive rises on US licensing deal for seizure drug with Eton Pharma